Aptamer-Based Antigen Delivery for Specific T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current carrier molecules for cell-mediated immunotherapies, such as antibodies and nanoparticles, often exhibit intrinsic immunostimulatory activity, cause undesired side effects, or have low stability, limiting their effectiveness in activating specific T cells through antigen-presenting cells.
Innovation Solution
Development of aptamers that specifically bind to antigen-presenting cells, are internalized, and localized within antigen processing compartments, facilitating targeted activation of specific T cells by conjugating antigenic peptides, thereby enhancing antigen presentation and processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional carrier molecules (antibodies, nanoparticles) are used to deliver antigens to antigen-presenting cells, then antigen delivery is achieved, but intrinsic immunostimulatory activity and undesired side effects occur
Solution Approach 1:
The patent extracts and removes the harmful immunostimulatory properties from the carrier molecule system by selecting aptamers that specifically bind to antigen-presenting cells without triggering non-specific immune activation. The aptamer carrier delivers antigens through a neutral, non-immunogenic mechanism, separating the delivery function from unwanted immunostimulatory effects.
Solution Approach 2:
The aptamer carrier provides localized, targeted delivery of antigens to specific antigen-presenting cells via high-affinity binding to cell surface receptors. This localized delivery ensures that antigen presentation occurs only at the intended target sites, improving specificity while avoiding systemic immunostimulation.
2Reliability
If conventional carrier molecules are used for antigen delivery, then antigen presentation is achieved, but stability and specificity are reduced
Solution Approach 1:
The patent changes the fundamental parameters of the carrier molecule by transitioning from protein-based (antibodies) or complex particulate (nanoparticles) systems to nucleic acid-based aptamers. This parameter change provides superior chemical stability, resistance to degradation, and tunable binding affinity, while eliminating batch-to-batch variability and immunogenicity associated with conventional carriers.
3Productivity
If complete ovalbumin protein is used without conjugation, then T cell activation occurs, but the mechanism is unclear and both CD4+ and CD8+ T cells are activated
Solution Approach 1:
The patent segments the antigen delivery mechanism into distinct functional components: the aptamer carrier handles targeted delivery to antigen-presenting cells, while the antigenic peptide component ensures specific MHC restriction. This segmentation allows independent optimization of delivery efficiency and antigen-specificity, resulting in controlled activation of either CD4+ or CD8+ T cells based on the peptide's MHC restriction rather than non-specific activation of both populations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamer-conjugated antigenic peptides effectively activate CD4+ and CD8+ T cells, demonstrating potential for aptamer-based DC vaccines in immunotherapeutic applications with reduced immunogenicity and improved specificity.
Implementation Method 1
the aptamer specifically binds a target on an antigen presenting cell
Implementation Method 2
upon contact with the cell, is internalized and wherein the aptamer is not immunostimulatory
Implementation Method 3
efficient antigen presentation and processing of aptamer conjugated antigenic peptides by antigen presenting cells
Data Source
AI summary
Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T-cell responses.